NCT04645199 National Longitudinal Cohort of Hematological Diseases
| NCT ID | NCT04645199 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,300 participants |
| Start Date | 2020-12-01 |
| Primary Completion | 2030-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,300 participants in total. It began in 2020-12-01 with a primary completion date of 2030-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The purpose of this study is to analyze the incidence and risk factors of major blood diseases, the treatment methods, prognosis and medical expenses of these patients in China. Method The study will include patients diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders, autoimmune hemolytic anemia, large granular lymphocyte leukemia, essential thrombocythemia, blood infection or received bone marrow transplantation in the investigating hospitals from January 1, 2020, and collect basic information, diagnostic and treatment information, prognosis information, as well as medical expense information from medical records. In its current form, the NICHE registry incorporates historical data (collected from 2000) and is systematically collecting prospective data in two phases with broadening reach, and prospectively follow-up to collect the prognosis information.
Eligibility Criteria
Inclusion Criteria: * Patients who were diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders or received bone marrow transplantation in the investigating hospitals from January 1, 2020. Exclusion Criteria: * Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease. * Alcohol and drug addictions affect their ability to comply with study requirements. * According to the investigator, there are conditions that may endanger the patient's safety or affect his/her compliance.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04645199 clinical trial?
This trial is open to participants of all sexes, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04645199 currently recruiting?
Yes, NCT04645199 is actively recruiting participants. Contact the research team at cir@ihcams.ac.cn for enrollment information.
Where is the NCT04645199 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT04645199 clinical trial?
NCT04645199 is sponsored by Institute of Hematology & Blood Diseases Hospital, China. The trial plans to enroll 2,300 participants.